Biohaven Ltd. (NYSE: BHVN) has agreed to license its entire Kv7 ion-channel platform, led by late-stage epilepsy candidate opakalim, to SK Biopharmaceuticals under a transaction carrying up to $795 million of payments and assumed obligations plus downstream royalties. Biohaven will receive $350 million at closing and another $50 million in 2027, giving it $400 million of near-term non-dilutive cash, while it remains eligible for another $150 million in development and regulatory milestones. SK will additionally assume specified Knopp Biosciences and future Kv7 obligations totaling up to $245 million, including up to $185 million linked to US and European opakalim approvals and another $60 million associated with future Kv7 programmes.
The timing makes the transaction especially notable. Opakalim, previously BHV-7000, is a selective Kv7.2/7.3 potassium-channel activator being developed as a once-daily oral antiseizure medicine, and enrollment in its pivotal RISE3 focal-epilepsy study was completed only in June. Topline results are expected during the second half of 2026, meaning SK is committing substantial capital before the principal late-stage focal-epilepsy efficacy result is available.
Why does Kv7 activation make sense as an epilepsy mechanism?
Neurons generate electrical signals partly through tightly regulated movement of ions across their membranes. Kv7.2 and Kv7.3 potassium channels contribute to the M-current, which acts as a stabilizing influence on neuronal excitability. Increasing that potassium current can make neurons less likely to fire repeatedly and pathologically, providing a mechanistically direct way to reduce seizure activity.
The target itself is not unvalidated. Earlier potassium-channel activators demonstrated that enhancing Kv7 activity can suppress seizures, but prior-generation approaches suffered from tolerability and other limitations that constrained long-term use. Biohaven has therefore designed opakalim around greater Kv7.2/7.3 selectivity, seeking antiseizure activity without the burden of central nervous system adverse effects that can undermine adherence to epilepsy medicines.
That differentiation is crucial because epilepsy does not lack approved drugs. The unmet need arises because a substantial population continues experiencing seizures despite treatment, while side effects such as somnolence, dizziness, cognitive impairment and coordination problems can limit how aggressively physicians can dose some therapies. Opakalim needs to show that selective channel activation changes that trade-off rather than simply introducing another mechanism into an already crowded treatment market.
What evidence does SK have before RISE3 reads out?
Biohaven has generated encouraging but not yet pivotal evidence across several epilepsy populations. In a randomized proof-of-concept study involving 27 participants with treatment-resistant idiopathic generalized epilepsy, median time to the second day with a generalized tonic-clonic seizure was 141 days with opakalim 75 mg once daily compared with 47 days on placebo. The study closed before reaching its planned enrollment because of recruitment difficulty and portfolio prioritization, and Biohaven did not provide formal statistical testing, meaning the result is an efficacy signal rather than confirmatory evidence.
The focal-epilepsy open-label extension has provided another signal. Biohaven reported that 54% of more than 100 evaluable participants receiving 75 mg once daily achieved at least a 50% reduction in seizure frequency during any consecutive six-month treatment period compared with their pretreatment baseline. Open-label extension results can be influenced by survivor and selection bias because patients tolerating or benefiting from therapy are more likely to remain enrolled, so those data cannot replace a randomized placebo-controlled pivotal result.
That is why RISE3 carries so much weight. The pivotal programme examines opakalim under randomized, double-blind and placebo-controlled conditions in adults with refractory focal epilepsy, with Biohaven expecting approximately 390 participants in each of its two pivotal studies. RISE3 evaluates 50 mg and 75 mg doses and uses change from baseline in 28-day average seizure frequency as the central efficacy measure.
Why is SK Biopharmaceuticals a logical buyer for this particular asset?
SK already built an epilepsy commercial franchise around XCOPRI, or cenobamate, giving it US neurology sales infrastructure, prescriber relationships and direct experience launching a differentiated antiseizure medicine. Acquiring opakalim therefore expands an area in which the company already understands clinical development, regulatory strategy and the economics of specialist commercialization rather than forcing it to create a new therapeutic-area organization.
The two medicines also operate through different mechanisms. Cenobamate modulates voltage-gated sodium channels and GABAergic transmission, while opakalim is designed around selective Kv7.2/7.3 activation. If opakalim succeeds, SK could eventually own complementary products capable of addressing different clinical needs within the same neurologist customer base.
For Biohaven, the strategic logic runs in the opposite direction. Building a commercial organization for one late-stage epilepsy product would require substantial capital precisely when the company has several other programmes competing for investment. Licensing the asset provides immediate cash, transfers much of the remaining development and commercialization burden to an experienced epilepsy company and preserves royalties if opakalim ultimately becomes successful.
How should the $795 million headline value be understood?
The transaction is more complex than a simple $795 million purchase price. Biohaven receives $400 million in near-term cash, consisting of $350 million at closing and $50 million in 2027, and can receive another $150 million directly through development and regulatory milestones. SK also assumes up to $245 million of obligations tied to Knopp Biosciences and future Kv7 programmes, bringing the combined potential platform-related commitments to $795 million.
Biohaven additionally retains tiered royalties ranging from the mid-teens to low twenties on US opakalim sales and a mid-single-digit royalty outside the United States. SK separately takes on mid-single-digit worldwide royalty obligations owed to Knopp Biosciences. The economic structure therefore distributes value among upfront cash, future milestones, assumed legacy obligations and recurring royalties rather than placing $795 million directly on Biohaven’s balance sheet at signing.
This matters when assessing development risk. A significant portion of SK’s potential financial exposure occurs only if opakalim advances successfully, while Biohaven has nevertheless secured unusually substantial near-term capital before RISE3 reports.
What happens if RISE3 disappoints?
The transaction would still have transferred $350 million at closing once closing conditions are met, and Biohaven would have reduced the future cost of maintaining the programme. SK would inherit an asset whose value could fall sharply if a properly powered pivotal focal-epilepsy study fails to demonstrate sufficient seizure reduction.
A negative RISE3 outcome would not automatically prove Kv7 activation has no therapeutic value. Dose selection, trial population, placebo response and epilepsy subtype could all influence results, and Biohaven has observed signals in idiopathic generalized epilepsy. But the commercial thesis is anchored first to focal epilepsy, where SK already has infrastructure and where regulatory approval requires a robust controlled data package.
Conversely, a strong RISE3 result could make the timing look advantageous for SK. Waiting for positive Phase 3 data would likely have raised the price of worldwide rights substantially and increased competition from other potential licensees.
Why is tolerability likely to matter almost as much as seizure reduction?
Epilepsy treatment is usually chronic, and many patients already take multiple antiseizure medications. A new therapy can produce statistically meaningful seizure reduction yet struggle commercially if it adds substantial dizziness, somnolence, cognitive slowing or coordination problems.
Biohaven has repeatedly emphasized what it considers a differentiated CNS tolerability profile for opakalim and has designed the drug for once-daily use without dose titration. Those attributes could simplify prescribing, but they remain part of the product’s proposed competitive profile until replicated across larger controlled studies and eventually a regulatory review.
The upcoming pivotal data therefore need to answer two linked questions: how much additional seizure control opakalim provides and what patients have to tolerate to obtain it. SK already has experience demonstrating that a differentiated epilepsy drug can build a meaningful specialist franchise. Its $795 million platform wager suggests it believes Kv7 activation can become the second pillar of that strategy.
The transaction has transferred the commercial question before the clinical question is fully answered. Biohaven has crystallized $400 million of near-term value and retained royalties, while SK acquires the platform just before RISE3 determines whether opakalim’s promising mechanistic and early clinical profile survives its most important randomized test.
